Current insight into diagnostics and pathophysiology o

Blood Reviews 22, 93-105 DOI: 10.1016/j.blre.2007.09.001

Citation Report

#	Article	IF	CITATIONS
1	Protein C supports platelet binding and activation under flow: role of glycoprotein lb and apolipoprotein E receptor 2. Journal of Thrombosis and Haemostasis, 2008, 6, 995-1002.	3.8	59
2	Does thrombophilia testing help in the clinical management of patients?. British Journal of Haematology, 2008, 143, 321-335.	2.5	145
3	Antiphospholipid syndrome. Arthritis Research and Therapy, 2008, 10, 230.	3.5	24
4	Mechanisms of Disease: antiphospholipid antibodies—from clinical association to pathologic mechanism. Nature Clinical Practice Rheumatology, 2008, 4, 192-199.	3.2	81
5	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus, 2008, 17, 938-943.	1.6	63
6	Diagnosis of antiphospholipid syndrome. Expert Review of Hematology, 2008, 1, 183-188.	2.2	1
9	Annexin A2 mediates anti-β2GPI/β2GPI-induced tissue factor expression on monocytes. International Journal of Molecular Medicine, 2009, 24, 557-62.	4.0	21
10	Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. European Journal of Haematology, 2009, 83, 1-16.	2.2	79
11	Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurology, The, 2009, 8, 998-1005.	10.2	370
12	Structural insights into recognition of β2â€g ycoprotein I by the lipoprotein receptors. Proteins: Structure, Function and Bioinformatics, 2009, 77, 940-949.	2.6	9
13	Concurrent thrombotic thrombocytopenic purpura and antiphospholipid syndrome: a rare and severe clinical combination. British Journal of Haematology, 2009, 147, 584-585.	2.5	7
14	β2-Clycoprotein I is incorrectly named apolipoprotein H. Journal of Thrombosis and Haemostasis, 2009, 7, 235-236.	3.8	54
15	An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. Journal of Thrombosis and Haemostasis, 2009, 7, 1541-1549.	3.8	33
16	Update of the guidelines for lupus anticoagulant detection. Journal of Thrombosis and Haemostasis, 2009, 7, 1737-1740.	3.8	1,055
17	Chapter 17 Treatment of Late Pregnancy Complications in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2009, 10, 203-214.	0.1	0
18	Detecting and Quantifying Functional Inhibitors in Hemostasis. , 2009, , 198-207.		3
19	Thrombotic risk factors: Basic pathophysiology. Critical Care Medicine, 2010, 38, S3-S9.	0.9	126
20	Mode of Interaction between β2GPI and Lipoprotein Receptors Suggests Mutually Exclusive Binding of β2GPI to the Receptors and Anionic Phospholipids. Structure, 2010, 18, 366-376.	3.3	27

	Сітатіо	CITATION REPORT	
#	Article	IF	CITATIONS
21	Differential expression of proteaseâ€activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis and Rheumatism, 2010, 62, 869-877.	6.7	52
22	Chemical synthesis and characterization of wildâ€type and biotinylated Nâ€terminal domain 1–64 of β2â€glycoprotein I. Protein Science, 2010, 19, 1065-1078.	7.6	23
23	Inherited thrombophilia and early pregnancy. , 0, , 131-142.		0
25	The role of LRP8 (ApoER2') in the pathophysiology of the antiphospholipid syndrome. Lupus, 2010, 19, 389-393.	1.6	18
26	Thrombophilia screening – at the right time, for the right patient, with a good reason. Clinical Chemistry and Laboratory Medicine, 2010, 48, S105-13.	2.3	12
27	Screening for coagulation disorders in patients with ischemic stroke. Expert Review of Neurotherapeutics, 2010, 10, 1321-1329.	2.8	10
28	Challenges in the Diagnosis of the Antiphospholipid Syndrome. Clinical Chemistry, 2010, 56, 930-940.	3.2	74
29	Les autoanticorps anti-phospholipides sont devenus bien hétérogènes. Immuno-Analyse Et Biologie Specialisee, 2011, 26, 47-54.	0.0	3
30	Antibodies to Domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thrombosis Research, 2011, 128, 583-586.	1.7	68
31	Inherited and Acquired Thrombophilia in Pregnancy. , 2011, , .		2
32	Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines. Journal of Thrombosis and Haemostasis, 2011, 9, 1776-1783.	3.8	29
33	Screening for lupus anticoagulant: improving the performance of the lupus-sensitive PTT-LA. International Journal of Laboratory Hematology, 2011, 33, 168-175.	1.3	2
34	Role of tumor necrosis factor- \hat{l}_{\pm} in the extraintestinal thrombosis associated with colonic inflammation. Inflammatory Bowel Diseases, 2011, 17, 2217-2223.	1.9	46
35	Antiphospholipid antibodies — We are not quite there yet. Blood Reviews, 2011, 25, 97-106.	5.7	45
36	Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus. Lupus, 2011, 20, 1474-1483.	1.6	19
37	Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis. Seminars in Thrombosis and Hemostasis, 2012, 38, 613-621.	2.7	14
38	Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders. Blood, 2012, 120, 4134-4142.	1.4	6
39	Antiphospholipid antibodies: Evaluation of the thrombotic risk. Thrombosis Research, 2012, 130, S37-S40.	1.7	48

CITATION REPORT

#	Article	IF	CITATIONS
40	Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome. European Journal of Internal Medicine, 2012, 23, 665-668.	2.2	11
42	Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs. Annales De Biologie Clinique, 2012, 70, 659-665.	0.1	2
43	The Clinical Significance of Coagulation and the Inflammatory Response in Autoimmunity. Clinical Reviews in Allergy and Immunology, 2012, 42, 172-180.	6.5	9
44	Thrombophilia and early pregnancy loss. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 91-102.	2.8	45
45	Antiphospholipid Antibodies in Dogs with Immune Mediated Hemolytic Anemia, Spontaneous Thrombosis, and Hyperadrenocorticism. Journal of Veterinary Internal Medicine, 2012, 26, 614-623.	1.6	8
47	The Dilute Russell's Viper Venom Time. Methods in Molecular Biology, 2013, 992, 341-348.	0.9	0
48	GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology, 2013, 52, 1397-1403.	1.9	248
49	Antiphospholipid Syndrome Antibodies — Snippets from the Laboratory. Proceedings of Singapore Healthcare, 2013, 22, 81-85.	0.6	1
50	The Clinical Significance of Posttranslational Modification of Autoantigens. Clinical Reviews in Allergy and Immunology, 2014, 47, 73-90.	6.5	31
51	Thrombophilic states. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 120, 1061-1071.	1.8	19
52	The role of <scp>TLR</scp> 4 in pathophysiology of antiphospholipid syndromeâ€associated thrombosis and pregnancy morbidity. British Journal of Haematology, 2014, 164, 165-176.	2.5	37
53	Thrombosis factors and oxidant/antioxidant markers in obese and hypertensive women during pregnancy. Blood Pressure, 2015, 24, 242-249.	1.5	5
54	Cutaneous manifestations in antiphospholipid syndrome. International Journal of Immunopathology and Pharmacology, 2015, 28, 270-273.	2.1	11
55	Bilan de thrombophilie dans la maladie thromboembolique veineuse. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2015, 2015, 20-22.	0.0	0
56	β2GP1, Anti-β2GP1 Antibodies and Platelets: Key Players in the Antiphospholipid Syndrome. Antibodies, 2016, 5, 12.	2.5	25
58	Autoantibodies and Biomarkers: Diagnostic Aspects. Rare Diseases of the Immune System, 2016, , 47-59.	0.1	0
59	Antiphospholipid syndrome: A diagnostic challenge. Medical Journal Armed Forces India, 2016, 72, S31-S36.	0.8	2
60	Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 47-69.	0.1	0

CITATION REPORT

#	Article	IF	CITATIONS
61	Treatment of Pregnancy Complications in Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, , 257-279.	0.1	0
63	Mechanisms of Cellular Activation in the Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2018, 44, 483-492.	2.7	20
64	Further Investigations of the Effects of Anti-β ₂ GP1 Antibodies on Collagen-Induced Platelet Aggregation. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1128-1133.	1.7	5
65	Hepatic manifestations in systemic lupus erythematosus. Lupus, 2020, 29, 813-824.	1.6	17
66	The prothrombotic state in cancer. Advances in Clinical Chemistry, 2021, 105, 213-242.	3.7	2
67	Antibodies to Phosphatidylserine/Prothrombin Complex in Antiphospholipid Syndrome. Advances in Clinical Chemistry, 2016, 73, 1-28.	3.7	18
68	A Novel Dimeric Inhibitor Targeting Beta2GPI in Beta2GPI/Antibody Complexes Implicated in Antiphospholipid Syndrome. PLoS ONE, 2010, 5, e15345.	2.5	27
69	Risk factors for venous and arterial thrombosis. Blood Transfusion, 2011, 9, 120-38.	0.4	294
70	High Prevalence of Antiphospholipid Antibodies in Children with Non-Transfusion Dependent Thalassemia and Possible Correlations with Microparticles. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020071.	1.3	2
71	Antiphospholipid syndrome, heritable thrombophilia and early pregnancy loss. Reproductive Medicine and Assisted Reproductive Techniques Series, 2008, , 349-356.	0.1	0
73	Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Open Access Macedonian Journal of Medical Sciences, 2014, 2, 544-549.	0.2	0
74	Testing lupus anticoagulants in a real-life scenario - a retrospective cohort study. Biochemia Medica, 2017, 27, 030705.	2.7	2